Cel-Sci herpes vaccine effective in mice tests

Maryland Watch

October 01, 1997

Cel-Sci Corp. said yesterday that a vaccine it is developing for herpes showed strong promise in a recent animal study.

The biotechnology company, which has its research and development offices in Baltimore, said mice immunized with the vaccine recovered from herpes infections more quickly and had fewer symptoms than mice that did not get the treatment. Results of the study were presented yesterday at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy in Toronto.

Publicly held Cel-Sci said the vaccine is made of a portion of the herpes simplex virus and a piece of a protein that binds to disease-fighting white blood cells, called T-cells. The company said early research shows that the combination not only stimulates an immune response but targets the response directly to the virus.

The Alexandria, Va.-based company said it is hoping to develop the vaccine as a prevention for the potentially serious disease and as a treatment for those suffering from it. There is no preventative available now for the disease, which affects an estimated 40 million to 60 million in the United States.

Pub Date: 10/01/97

Baltimore Sun Articles
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.